35436-74-9

Basic information

• Product Name: AC-DL-LYS (AC)-OH
• Synonyms: AC-DL-LYS (AC)-OH;AC-DL-LYSINE (AC)-OH;N-ALPHA,EPSILON-DIACETYL-DL-LYSINE;N-ALPHA,EPSILON-BIS-ACETYL-DL-LYSINE;N2,N6-Diacetyl-DL-lysine
• CAS NO: 35436-74-9
• Molecular Formula: C₁₀H₁₈N₂O₄
• Molecular Weight: 230.26
• Mol File: 35436-74-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 140-141 °C
• Boiling Point: 578.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.148±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.65±0.10(Predicted)
• CAS DataBase Reference: AC-DL-LYS (AC)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: AC-DL-LYS (AC)-OH(35436-74-9)
• EPA Substance Registry System: AC-DL-LYS (AC)-OH(35436-74-9)

Safety Data

• Hazardous Substances Data: 35436-74-9(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 72, p. 5137, 1950 DOI: 10.1021/ja01167a091

Upstream product

• 56-87-1 L-lysine 
• 357657-22-8 lysine acetylsalicylate 
• 50-78-2 aspirin 

Downstream Products

• 105707-01-5 diacetyllysine S-α-phenylethylamide 
• 181182-84-3 (S)-2,6-Bis-acetylamino-hexanoic acid 2-nitro-phenyl ester 
• 181182-85-4 (R)-2-[2-((S)-2,6-Bis-acetylamino-hexanoylamino)-ethanesulfonylamino]-propionic acid benzyl ester 

Relevant articles and documents

Interactions of acetylsalicyclic acid and lysine in solution

-

Antibacterial amide compounds and means for using the same

Novel organic amide compounds which are N-[6-[(acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinyl] penicillin compounds having broad spectrum antibacterial utility are provided by (a) reacting the free amino acid of the appropriate penicillin or the acid salt or silylated derivative or complex thereof with a reactive derivative of the corresponding N-6-[(acylaminoacylamino or aminoacylamino)-phenyl]-1,2-dihydro-2-oxonicotinic acid or (b) reacting the free amino acid 6-aminopenicillanic acid or a related compound or the acid salt or silylated derivative thereof with a reactive derivative of the corresponding D-N-[6-[(acylaminoacylamino or aminoacylamino) phenyl]-1,2-dihydro-2-oxonicotinyl]-2-substituted glycine. Pharmaceutical compositions containing said compounds and methods for treating infections using said compositions are also disclosed.